The Analysis of Scientific Data on the Efficacy of Pneumococcal Conjugated Vaccine in the Cohort of Children with Bronchial Asthma

The Analysis of Scientific Data on the Efficacy of Pneumococcal Conjugated Vaccine in the Cohort of Children with Bronchial Asthma

This article refutes one popular-science review that has appeared on the MDedge news site in January 2020. It has stated that there was no effect of vaccination with 7-valent pneumococcal conjugate vaccine (PCV-7) against invasive forms of Streptococcus pneumoniae in children with bronchial asthma....

Full description

Saved in:

Bibliographic Details
Main Authors:	Tatiana A. Kaliuzhnaia, Marina V. Fedoseenko, Leyla S. Namazova-Baranova, Firuza Ch. Shakhtakhtinskaya, Arevaluis M. Selvyan, Svetlana V. Tolstova, Tatiana E. Privalova
Format:	Article
Language:	Russian
Published:	Union of pediatricians of Russia 2020-11-01
Series:	Педиатрическая фармакология
Subjects:	vaccination pneumococcal conjugate vaccine bronchial asthma popular-science review invasive pneumococcal disease pneumococcal serotypes pneumococcal polysaccharide vaccine
Online Access:	https://www.pedpharma.ru/jour/article/view/1909
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

NEXT GENERATION PNEUMOCOCCAL CONJUGATE VACCINES EFFICACY AND EFFECTIVENESS IN DIFFERENT REGIONS OF THE WORLD
by: O. P. Kovtun, et al.
Published: (2014-01-01)

EFFECTIVENESS OF THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE: EMERGING DATA FROM INVASIVE PNEUMOCOCCAL DISEASE, PNEUMONIA, ACUTE OTITIS MEDIA AND NASOPHARYNGEAL CARRIAGE
by: Ralf Rene Reinert, et al.
Published: (2012-06-01)

Vaccine Prevention of Pneumococcal Infection in Children
by: Alexander A. Baranov, et al.
Published: (2018-07-01)

Global distribution and characteristics of pneumococcal serotypes in adults
by: Haruka Maeda, et al.
Published: (2025-12-01)

Strategies for pneumococcal vaccination in older adults in the coming era
by: Kei Nakashima, et al.
Published: (2024-12-01)

Vaccinal Prevention of Lower Respiratory Tract Pneumococcal Disease in Adults Without Immunosuppression
by: I. A. Guchev
Published: (2020-05-01)

Vaccinal Prevention of Pneumococcal Infection in Children
by: A. A. Baranov, et al.
Published: (2015-12-01)

A decade of 10-valent pneumococcal conjugate vaccine use in Lithuania: trends in invasive pneumococcal serotype dynamics
by: Aurelija Petrutienė, et al.
Published: (2025-08-01)

Pneumococcal serotype prevalence and antibiotic resistance in children in South and Southeast Asia, 2012–2024
by: Tzou-Yien Lin, et al.
Published: (2024-12-01)

Epidemiology of Streptococcus pneumoniae serotypes in children before and after pneumococcal vaccination
by: I. N. Protasova, et al.
Published: (2021-12-01)

Bronchopulmonary Pathology Prevalence Among Premature infants and Estimation of Prophylactic Efficacy and Reactogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Premature infants with Bronchopulmonary Dysplasia
by: Vladislav V. Semerikov, et al.
Published: (2020-02-01)

Serotype 3 invasive pneumococcal disease in Tuscany across the eras of conjugate vaccines (2005–2024) and anthropic-driven respiratory virus fluctuations
by: Lorenzo Lodi, et al.
Published: (2025-12-01)

The New Era of Pneumococcal Vaccination in Adults: What Is Next?
by: Lale Ozisik
Published: (2025-05-01)

Pneumococcal conjugate 7-valent vacciPNEUMOCOCCAL CONJUGATE 7-VALENT VACCINE IN CHILDREN. REGIONAL EXPERIENCEne in children. Regional experience
by: N. L. Chernaya, et al.
Published: (2012-02-01)

An economic evaluation of pneumococcal conjugate vaccines, PCV20 versus PCV15, for the prevention of pneumococcal disease in the Swedish pediatric population
by: Ann-Charlotte Fridh, et al.
Published: (2024-12-01)

Bacterial Acute Otitis Media Complicated with Otorrhea in a Children’s Hospital in the Era of Pneumococcal Conjugate Vaccines
by: Irene Tzovara, et al.
Published: (2025-05-01)

Real-World Impact of Pneumococcal Conjugate Vaccines on Vaccine Serotypes and Potential Cross-Reacting Non-Vaccine Serotypes
by: Kevin Apodaca, et al.
Published: (2025-06-01)

A Phase 3 Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Adult-Specific Pneumococcal Vaccine, Compared with PPSV23, in Adults ≥50 Years of Age (STRIDE-10)
by: Veronika Jotterand, et al.
Published: (2025-03-01)

EXPERIENCE OF APPLICATION AND SAFETY ASSESSMENT OF THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN UNDER-5 CHILDREN
by: M. V. Fedoseenko, et al.
Published: (2014-09-01)

A narrative review of pneumococcal serotypes causing invasive disease in North Africa and the Middle East
by: Hammam Haridy, et al.
Published: (2025-08-01)

Serotype distribution among adults with community-acquired pneumococcal pneumonia in Japan between 2019 and 2022: A multicenter observational study
by: Haruka Maeda, et al.
Published: (2025-12-01)

Pneumococcal vaccination in older adults: A useful, but underused weapon
by: Filipić Brankica
Published: (2025-01-01)

Pneumococcal disease: emergence of serotypes 19A and 7F following conjugate pneumococcal vaccination in a Mexican hospital
by: Enrique Chacon-Cruz, et al.
Published: (2011-12-01)

Pneumococcal vaccine hyporesponsiveness in people living with HIV: A narrative review of immunological mechanisms and insights from minimally invasive lymph node sampling
by: Giovanni E. Loe-Sack-Sioe, et al.
Published: (2025-12-01)

Pneumococcal Vaccine Uptake in Adults Before and After Hospitalization for Pneumococcal Infections in Hong Kong, 2015 to 2024
by: King-Pui Florence Chan, et al.
Published: (2025-05-01)

Analysis of pneumococcal serotypes distribution to determine a model composition for a Russian pneumococcal conjugate vaccine
by: V. P. Trukhin, et al.
Published: (2022-07-01)

A population-based study on the burden of hospitalized pediatric pneumococcal disease in Taiwan before and after the introduction of 13-valent pneumococcal conjugate vaccine into the childhood immunization program in 2015
by: Ting-An Yen, et al.
Published: (2025-02-01)

13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE
by: V. K. Tatochenko, et al.
Published: (2012-03-01)

PHARMACOECONOMIC ASSESSMENT OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN IMMUNIZATION OF CHILDREN IN RUSSIAN FEDERATION
by: A. V. Rudakova, et al.
Published: (2014-01-01)

What do Patients Know About Pneumococcal Vaccine?
by: Fatma Çiftci, et al.
Published: (2017-08-01)

Efficacy of conjugate vaccines in pneumococcal infection prevention
by: A. L. Perova, et al.
Published: (2014-09-01)

Cost-Effectiveness Analysis of the Use of V116, a 21-Valent Pneumococcal Conjugate Vaccine, in Vaccine-Naïve Adults Aged ≥ 65 Years in the United States
by: Zinan Yi, et al.
Published: (2024-11-01)

Clinical burden of pneumococcal disease among adults in France: A retrospective cohort study
by: M. Doyinsola Bailey, et al.
Published: (2025-12-01)

Modern Approaches to Vaccinal Prevention of a Pneumococcal Infection in Adults Patients with Diabetes Mellitus (Literature Review)
by: J. A. Paramonova, et al.
Published: (2018-04-01)

Serotype distribution of invasive and non-invasive pneumococcal disease in children ≤5 years of age following the introduction of 10- and 13-valent pneumococcal conjugate vaccines in infant national immunization programs: a systematic literature review
by: Patricia Izurieta, et al.
Published: (2025-05-01)

VACCINATION AGAINST PNEUMOCOCCAL INFECTIONS IN RUSSIAN FEDERATION: SOCIAL AND PHARMACOECONOMIC ASPECTS
by: A. V. Rudakova, et al.
Published: (2018-10-01)

Pneumococcal disease in children in the Middle East and Northern Africa: A systematic literature review of clinical burden, serotype distribution, and vaccination programs
by: Dzhumber Ugrekhelidze, et al.
Published: (2024-12-01)

A cost-effectiveness analysis of the 20-valent pneumococcal conjugate vaccine for the prevention of pneumococcal disease among Mexican adults aged ≥60 years
by: Jose Luis Huerta, et al.
Published: (2025-08-01)

Pneumococcal Infection and Vaccination-Related Knowledge, Attitudes and Practices Among Saudi Residents
by: Wed S. Althobaiti, et al.
Published: (2025-07-01)

Serotype-specific serum immunoglobulin G at 18 months of age following one or two doses of a primary series of 10-valent or 13-valent pneumococcal conjugate vaccine and a booster dose at nine months of age: a randomized controlled study
by: Alane Izu, et al.
Published: (2025-12-01)